Every S-3 that Kala Pharmaceuticals Inc (KALA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow KALA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KALA filings page.
KALA BIO, Inc. files an Amendment No. 1 to a shelf registration to replace its prior registration and register unsold securities under Rule 415, and provides a prospectus for up to $350,000,000 of securities. The filing carries forward an aggregate of $327,820,467 of unsold securities from the prior registration statement under Rule 415(a)(6).
The company discloses a 1-for-50 reverse stock split effective May 8, 2026, which reduced shares outstanding from 929,491,578 to 18,589,787. The filing reflects the split-adjusted impact on weighted-average shares and basic and diluted net loss per share for the years ended December 31, 2025 and 2024, and states that most share counts and per-share amounts in the prospectus are presented on a pre–Reverse Stock Split basis.
KALA BIO, Inc. filed a shelf registration statement on to offer up to $350,000,000 of securities, replacing a prior registration and carrying forward $327,820,467 of unsold securities from the prior filing under Rule 415(a)(6). The company discloses its strategic pivot from its MSC-S clinical program toward monetizing legacy biologics assets and testing an exclusive license of the Researgency on‑premises AI research platform for biotechnology customers.
The filing confirms the suspension of development of KPI-012 after the CHASE Phase 2b trial failed to meet primary and key secondary endpoints, a workforce reduction of ~19 employees (~51%), and a 1-for-50 reverse stock split effective May 8, 2026 (reducing outstanding shares from 929,491,578 to ~18,589,832). Trading will resume on a split‑adjusted basis on Nasdaq on May 11, 2026 under the symbol "KALA."
KALA BIO, Inc. files a resale registration covering up to 241,435,910 shares of common stock for existing stockholders. The shares include 238,335,910 shares from preferred stock conversions, 2,200,000 shares issued to LifeSci Capital LLC, and 900,000 settlement shares issued to Baker Brothers entities.
All shares may be sold from time to time by the selling stockholders, and KALA will not receive any proceeds from these sales, though it will pay registration expenses. As context, 911,330,225 shares of common stock were outstanding as of February 4, 2026. The filing also highlights Nasdaq notices that KALA is currently below market‑value and minimum bid‑price listing requirements, creating a risk of potential delisting if compliance is not regained.